![[current-page:title] logo](/sites/default/files/styles/logo/public/default_images/_no-logo.png?itok=8OH0tuUw){kind=logo}
Founded
Address
Enobia Pharma Corp
2901 Rachel Street
Suite 23
Montreal QC H1W 4A4
Canada
Enobia Pharma Corp
2901 Rachel Street Suite 23
Montreal QC H1W 4A4
Canada
Enobia Pharma Corp
C/o Enobia Pharma Corp 2901 Rachel Street
Suite 23
Montreal QC H1W 4A4
Canada
Enobia Pharma Corp
C/o Enobia Pharma Inc
2901 Rachel Street Suite 23
Montreal QC H1W 4A4
Canada
Phone
Website
KANDO id: 380701
Corporate information
Official name
Enobia Pharma Corporation
Registration country
Official identities
US CIK 0001412621
Funding rounds
Acquisition USD 1,100,000,000
USD 1,100,000,000 ( ) at USD 1,100,000,000 pre-money valuation
| Investor | Profile | Country | Notes | |
|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Alexion Pharmaceuticals Inc | Complement inhibition for cardiovascular and inflammatory diseases. | USD 1,100,000,000 (USD 1,100,000,000) |
Series B
( )
| Investor | Profile | Country | |
|---|---|---|---|
|
OrbiMed Advisors LLC | American investment firm focused on making public and private investments in the healthcare and biotechnology industries. |
| Investor | Profile | Country | |
|---|---|---|---|
|
|
Solidarity Fund QFL (Fonds de solidarité FTQ), (Fonds de solidarite FTQ) |
Investment activity status
Active investor